Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein, Inc. reports developments across its health care distribution, practice solutions, and dental technology businesses. The company serves office-based dental and medical practitioners, dental laboratories, government and institutional health care clinics, and other alternate care sites through business, clinical, technology, and supply chain solutions.
Recurring news themes include earnings releases, financial guidance, investor conference participation, board and executive governance updates, and product announcements from Henry Schein One. Recent technology coverage centers on Dentrix Ascend, a cloud-based dental platform that integrates practice management, clinical workflows, imaging, revenue cycle management, analytics, patient experience tools, and AI-enabled workflow capabilities.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.
Henry Schein (HSIC) will present at the J.P. Morgan Healthcare Investor Conference on Tuesday, January 13, 2026 at 3:00 p.m. PST / 6:00 p.m. EST at The Westin St. Francis in San Francisco.
Presentations will be available live via webcast at www.henryschein.com/IRwebcasts, with replays posted on the Henry Schein investor website after the event. The company provides health care solutions to office-based dental and medical practitioners.
Henry Schein (Nasdaq: HSIC) said its board expects to appoint the company's next CEO by mid-January 2026. The board described the search as nearing completion after evaluating a pool of highly qualified candidates with exceptional interest and caliber. The company confirmed the decision will not be finalized before year-end and that Stanley Bergman will continue as CEO & Chairman at the board’s request until a successor assumes the role.
The announcement frames a targeted timeline for leadership transition while emphasizing continuity of operations and a planned, orderly handover.
Henry Schein (Nasdaq: HSIC) expanded its agreement with vVARDIS to become the exclusive U.S. distributor of Curodont™ Repair Fluoride Plus across all dental market segments, effective January 1, 2026.
The expanded deal broadens prior 2024 exclusivity for Dental Service Organizations to include general dentistry, orthodontics, and pediatric dentistry nationwide. vVARDIS founders report having accessed over 10% of U.S. dental offices and treated more than 500,000 patients with Curodont. Henry Schein is currently the market leader selling Curodont to general practitioners and DSOs in the U.S. The product offers a drill- and needle-free treatment for early-stage cavities, which the companies describe as an opportunity to increase in-office care for untreated early lesions.
Henry Schein One (NASDAQ:HSIC) unveiled natively embedded AI workflows for Dentrix and Dentrix Ascend at the 2025 Greater New York Dental Meeting (Nov 30–Dec 3, 2025). Key features include Voice Notes for real-time chairside transcription and summaries, Forms that capture insurance data from a photo, Eligibility Pro for real-time benefits, and Detect AI (FDA-cleared) for x‑ray diagnostics. The company also announced Phones integration, a multilingual 24/7 assistant Claire, and plans for predictive scheduling, coding assistants, and unified analytics to improve intake, claims accuracy, and practice efficiency.
Henry Schein (Nasdaq: HSIC) will present at Piper Sandler’s Healthcare Conference on December 2, 2025 at 9:00 a.m. ET at the Lotte New York Palace Hotel in New York.
Investors can listen to the presentation via live webcast at www.henryschein.com/IRwebcasts. Replays will be posted on the Henry Schein investor website after the presentation.
VideaHealth and Henry Schein One (HSIC) launched the Impact Panel, an enhancement to Detect AI that embeds real-time AI findings and patient education directly into Dentrix and Dentrix Ascend imaging workflows on November 5, 2025.
Key features include an interactive odontogram, AI summaries showing tooth damage percentages and bone-level summaries by quadrant, on-screen diagrams, QR codes and print options. The Impact Panel is included at no additional cost for Detect AI users. Practices using the QR feature have reported a 19% increase in case acceptance.
Summary not available.
Henry Schein One (NYSE:HSIC) announced a strategic partnership with AWS to integrate generative AI across its dental platforms, including Dentrix, Dentrix Ascend, and Dentally. The initiative targets AI-native workflows for scheduling, imaging, documentation, claims validation, pricing, and patient engagement to reduce administrative burden and improve outcomes.
The rollout will leverage AWS services such as Amazon Bedrock and Transcribe Medical and aims for global scalability across the U.S., U.K., and E.U. The companies emphasize security, regulatory compliance, and interoperability as core design principles.
Henry Schein (Nasdaq: HSIC) will present at two investor conferences in November 2025 and provide live webcasts and replays.
Presentations: Stifel Healthcare Conference at Lotte New York Palace Hotel on November 12, 2025 at 11:20 AM ET, and Jefferies Healthcare Conference at ME Hotel London on November 18, 2025 at 2:30 PM GMT / 9:30 AM ET. Webcasts and replays will be available at www.henryschein.com/IRwebcasts.